GLOBAL INVESTOR STATEMENT
IN SUPPORT OF AN EFFECTIVE, FAIR AND EQUITABLE GLOBAL RESPONSE TO COVID-19

As of 16 April 2021, this statement has already been signed by 158 institutional investors and their representatives with over USD$ 15 trillion in assets under management or advice. The statement is still open for signature.

As institutional investors with millions of beneficiaries around the world, we recognise and attach considerable importance to the need for an effective, fair and equitable global response to COVID-19. For this reason, we are concerned about the negative impact that limited funding for the Access to COVID-19 Tools (ACT) Accelerator and uneven global access to health technologies (from vaccines and monoclonal antibodies to diagnostics and medical oxygen) will have on the trajectory of the pandemic and global economic activity in the coming years.

A study commissioned by the International Chamber of Commerce Research Foundation has found that advanced economies that can vaccinate all of their citizens remain at risk of a sluggish recovery with a drag on GDP if infection continues to spread unabated in emerging markets. In fact, the global economy stands to lose as much as US$ 9.2 trillion if governments fail to ensure that developing economies gain access to COVID-19 vaccines. These losses dwarf the funding needed to enable vaccines to be procured for everyone, everywhere – making a clear “investment case” for full capitalization of the ACT-Accelerator and a coordinated global approach to distribution.

A different study commissioned by the Bill & Melinda Gates Foundation has reached a similar conclusion: leaving lower-income countries without access to vaccines amid the COVID-19 pandemic will cause significant economic damage that puts decades of economic progress at risk – for both emerging markets and advanced economies alike. The report has estimated that the economic benefits of a global equitable vaccine solution alone for the 10 countries included in the analysis would be at least US$ 153 billion in 2020-21, rising to US$ 466 billion by 2025. This is more than 12 times the US$ 38 billion estimated total cost of the ACT-Accelerator.

Given the pervasive health and social costs of the pandemic, we recognise a strong moral argument to leave no one behind. The two reports above highlight that empowering an effective, fair and equitable global response to COVID-19 via the ACT-Accelerator in 2021 is not only the right thing to do – it also makes full economic sense. We therefore:

a) Encourage world leaders in the G7, G20 and ACT-Accelerator Facilitation Council to finance the ACT-Accelerator in full and deploy adequate funding to ensure fair and equitable access to COVID-19 tools globally;

b) Commit to work with the Access to Medicine Foundation on this issue and engage (bilaterally and/or via existing collaborative initiatives) with our investee healthcare companies to promote industry actions supporting the mission and operations of the ACT-Accelerator (e.g., cross-industry partnerships to accelerate R&D and expand production, equitable pricing strategies, voluntary licensing agreements); and

c) Recommend that governments and international organisations explore the feasibility of innovative finance mechanisms for national and global COVID-19 responses, similar to vaccine bonds issued by the International Finance Facility for Immunisation or social bonds for COVID-19 programmes issued by individual or multiple governments. These mechanisms could build on the strong response by capital markets to ESG-labelled debt issued in 2020.

The International Monetary Fund has urged the international community to act quickly to make sure that COVID-19 health technologies are available globally to mitigate the risks of virus mutations and address what is currently a deeply iniquitous distribution of COVID-19 tools across the world.

We support this call for action. The time to act is now.
<table>
<thead>
<tr>
<th>SIGNATORY INVESTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Listed in alphabetical order by organisation name. Total assets under management in excess of USD$ 14 trillion.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>a.s.r. asset management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achmea</td>
</tr>
<tr>
<td>ACTIAM</td>
</tr>
<tr>
<td>Adrian Dominican Sisters, Portfolio Advisory Board</td>
</tr>
<tr>
<td>Aegon Asset Management</td>
</tr>
<tr>
<td>Aegon Netherlands</td>
</tr>
<tr>
<td>Aequo</td>
</tr>
<tr>
<td>AkademikerPension</td>
</tr>
<tr>
<td>Alecta pensionsförsäkring, omsesidigt</td>
</tr>
<tr>
<td>Align Impact</td>
</tr>
<tr>
<td>AllianceBernstein</td>
</tr>
<tr>
<td>Alquity Investment Management Limited</td>
</tr>
<tr>
<td>Alternative Bank Schweiz (member of Shareholders for Change)</td>
</tr>
<tr>
<td>American Century Investments</td>
</tr>
<tr>
<td>AMP Capital</td>
</tr>
<tr>
<td>ANDA Asset Management Co., Ltd</td>
</tr>
<tr>
<td>Andbank Wealth Management SGIIC</td>
</tr>
<tr>
<td>AP7 (Sjunde AP-fonden)</td>
</tr>
<tr>
<td>ASN Beleggingsfondsen</td>
</tr>
<tr>
<td>Asset Management One</td>
</tr>
<tr>
<td>Australian Ethical Investment</td>
</tr>
<tr>
<td>Avaron Asset Management</td>
</tr>
<tr>
<td>Aviva Investors</td>
</tr>
<tr>
<td>Aware Super</td>
</tr>
<tr>
<td>AXA Investment Managers</td>
</tr>
<tr>
<td>Baloise Asset Management</td>
</tr>
<tr>
<td>BancoPosta Fondi Sgr</td>
</tr>
<tr>
<td>Bank für Kirche und Caritas eG (member of Shareholders for Change)</td>
</tr>
<tr>
<td>BanSabadell Pensiones E.G.F.P., S.A.</td>
</tr>
<tr>
<td>BBVA Asset Management</td>
</tr>
<tr>
<td>Joh. Berenberg, Gossler &amp; Co. KG (Berenberg)</td>
</tr>
<tr>
<td>BlueBay Asset Management</td>
</tr>
<tr>
<td>BMO Global Asset Management</td>
</tr>
<tr>
<td>BNP Paribas Asset Management</td>
</tr>
<tr>
<td>Bon Secours Mercy Health</td>
</tr>
<tr>
<td>Boston Common Asset Management</td>
</tr>
<tr>
<td>Boston Trust Walden</td>
</tr>
<tr>
<td>CANDRIAM</td>
</tr>
<tr>
<td>Castlefield Investment Partners</td>
</tr>
<tr>
<td>Central Finance Board of the Methodist Church</td>
</tr>
<tr>
<td>Church of Sweden</td>
</tr>
<tr>
<td>The Church Pension Fund (Finland)</td>
</tr>
<tr>
<td>ClearBridge Investments</td>
</tr>
<tr>
<td>Coho Partners</td>
</tr>
<tr>
<td>Columbia Threadneedle</td>
</tr>
<tr>
<td>Comgest</td>
</tr>
<tr>
<td>CommonSpirit Health</td>
</tr>
<tr>
<td>Compañía de servicios de bebidas refrescantes pensiones, F.P</td>
</tr>
<tr>
<td>Congregation of St. Joseph</td>
</tr>
<tr>
<td>Cooperaatie VGZ U.A.</td>
</tr>
<tr>
<td>The Dai-ichi Life Insurance Company, Limited</td>
</tr>
<tr>
<td>Dana Investment Advisors</td>
</tr>
<tr>
<td>Daughters of Charity, Province of St. Louis</td>
</tr>
<tr>
<td>DNB Asset Management</td>
</tr>
<tr>
<td>Domini Impact Investments LLC</td>
</tr>
<tr>
<td>E &amp; D Group</td>
</tr>
<tr>
<td>Ecofi (member of Shareholders for Change)</td>
</tr>
<tr>
<td>EFG Asset Management</td>
</tr>
<tr>
<td>Egamo</td>
</tr>
<tr>
<td>EOS at Federated Hermes</td>
</tr>
<tr>
<td>Ethical Partners Funds Management</td>
</tr>
<tr>
<td>Ethos (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Etica Funds (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Everence and the Praxis Mutual Funds</td>
</tr>
<tr>
<td>Fair-finance Vorsorgekasse (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Fidelity International</td>
</tr>
<tr>
<td>The Folksam Group</td>
</tr>
<tr>
<td>Fondazione Finanza Etica (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Fondo de Pensiones de los Empleados de Banco Sabadell GM</td>
</tr>
<tr>
<td>Fondo de Pensiones de los Empleados de Banco Sabadell MF2000</td>
</tr>
<tr>
<td>Fondo Pensione per il Personale delle Aziende del gruppo Unicredit</td>
</tr>
<tr>
<td>Forma Futura (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Forum Equity Partners</td>
</tr>
<tr>
<td>Friends Provident Foundation (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Fundación Finanzas Eticas (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Future Super</td>
</tr>
<tr>
<td>GAM Investments</td>
</tr>
<tr>
<td>Genesis Investment Management</td>
</tr>
<tr>
<td>GMO</td>
</tr>
<tr>
<td>De Goudse Verzekeringen</td>
</tr>
<tr>
<td>Groupama Asset Management</td>
</tr>
<tr>
<td>HESTA</td>
</tr>
<tr>
<td>Hexavest</td>
</tr>
<tr>
<td>ICCR</td>
</tr>
<tr>
<td>Impact Investors</td>
</tr>
<tr>
<td>Impax Asset Management</td>
</tr>
<tr>
<td>Indecap Fonder AB</td>
</tr>
<tr>
<td>Insight Investment</td>
</tr>
<tr>
<td>ISGAM AG</td>
</tr>
<tr>
<td>Jilens Investor Network</td>
</tr>
<tr>
<td>Jupiter Asset Management</td>
</tr>
<tr>
<td>KBI Global Investors</td>
</tr>
<tr>
<td>Kempen Capital Management</td>
</tr>
<tr>
<td>KLP Kapitalforvaltning AS</td>
</tr>
<tr>
<td>Lånsförsäkringar Liv AB</td>
</tr>
<tr>
<td>La Banque Postale Asset Management</td>
</tr>
<tr>
<td>La Financière de l'Echiquier</td>
</tr>
<tr>
<td>Liontrust Asset Management PLC</td>
</tr>
<tr>
<td>Local Government Super</td>
</tr>
<tr>
<td>London LGPS CIV Ltd</td>
</tr>
<tr>
<td>M&amp;G Investments</td>
</tr>
<tr>
<td>Man Group plc</td>
</tr>
<tr>
<td>MedRisk</td>
</tr>
<tr>
<td>Meeschaert Asset Management (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Mercy Investment Services, Inc.</td>
</tr>
<tr>
<td>Midat Cyclops, FP</td>
</tr>
<tr>
<td>Miller/Howard Investments</td>
</tr>
<tr>
<td>Mirova</td>
</tr>
<tr>
<td>Montanaro Asset Management</td>
</tr>
<tr>
<td>Mutualitat dels Enginyers MPS</td>
</tr>
<tr>
<td>NEI Investments</td>
</tr>
<tr>
<td>Newground Social Investment</td>
</tr>
<tr>
<td>NN Investment Partners</td>
</tr>
<tr>
<td>Nomura Asset Management</td>
</tr>
<tr>
<td>Nordea Asset Management</td>
</tr>
<tr>
<td>Northwest Coalition for Responsible Investment</td>
</tr>
<tr>
<td>OFI Asset Management</td>
</tr>
<tr>
<td>Öhman</td>
</tr>
<tr>
<td>Paedagogernes Pension (PBU)</td>
</tr>
<tr>
<td>Parnassus Investments</td>
</tr>
<tr>
<td>Poste Vita S.p.A.</td>
</tr>
<tr>
<td>Providence Capital NV</td>
</tr>
<tr>
<td>RAM Active Investments SA</td>
</tr>
<tr>
<td>Rathbone Greenbank Investments</td>
</tr>
<tr>
<td>Reyners, McVeigh Capital Management, LLC</td>
</tr>
<tr>
<td>Robeco</td>
</tr>
<tr>
<td>San Francisco Employees' Retirement System (SFERS)</td>
</tr>
<tr>
<td>SANSO Investment Solutions (member of Shareholders for Change)</td>
</tr>
<tr>
<td>Schroders</td>
</tr>
<tr>
<td>SEB Investment Management AB</td>
</tr>
<tr>
<td>Shareholders for Change</td>
</tr>
<tr>
<td>The Sisters of St Francis of Philadelphia</td>
</tr>
<tr>
<td>The Socially Responsible Investing Group of 1919 Investment Counsel</td>
</tr>
</tbody>
</table>
This investor statement is coordinated by the Access to Medicine Foundation, an independent, non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine. It publishes the Access to Medicine Index and the Antimicrobial Resistance Benchmark. The Foundation is funded by the UK Foreign, Commonwealth and Development Office, the Dutch Ministry of Foreign Affairs, Dutch Ministry of Health, Welfare and Sport, the Bill & Melinda Gates Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, AXA Investment Managers and Wellcome Trust.

Updated January 2022